A federal jury in California has found that Axonics’ neurostimulators and electric leads for treating incontinence do not run ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

The Court for the Central District of California has sided with Axonics finding the company did not breach Medtronic’s ...

Meanwhile, Boston Scientific is still waiting for antitrust regulators to conclude their review of its proposal to buy Axonics, which was announced in January.

Axonics (Nasdaq:AXNX) announced today that a jury unanimously ruled in its favor in a patent spat with (NYSE: MDT).

Axonics, Inc. (AXNX) comes out victorious in a patent trial against Medtronic (MDT), as the jury rules in its favor, awarding ...

Shares of Medtronic PLC climbed toward a three-month high in early Tuesday trading, after the medical-technology company topped fiscal first-quarter earnings expectations, amid strength in its ...

Aug 20 (Reuters) - Medtronic (MDT.N), opens new tab slightly lifted the lower end of its annual profit forecast on Tuesday, banking on sustained demand for its medical devices and growth from its ...

Medical device giant Medtronic (NYSE: MDT) has been somewhat of a stock market laggard over the past five years, partly due to pandemic-related disruptions. Even beyond this global issue ...

Medtronic delivered a strong first-quarter earnings report. The company benefits from continued market adoption of several new product launches over the past year. The stock looks attractive ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Investors signalled that they were pleased with Medtronic plc's (NYSE:MDT) most recent earnings report. Looking deeper at the numbers, we found several encouraging factors beyond the headline ...